Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance. "A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx™ or placebo shows a lower level of pericarditis recurrence th